In a recent InvestorNews interview with host Tracy Weslosky, Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director, Greg Fenton, discussed China’s recent move to restrict graphite exports and its potential impact on global supply chains and the electric vehicle (EV) industry.

Concerns about China’s dominance in supplying critical minerals to the EV industry have prompted governments to identify this as a significant risk. Greg said that the recent restrictions on graphite exports highlight the importance of creating a North American battery supply chain. Greg underscored the potential for this situation to significantly alter the EV landscape. Foreseeing long-term growth, Greg discussed why electric vehicle manufacturers will need to diversify their supply chains away from China.

Greg believes these restrictions will shift the focus to North American graphite producers. Highlighting Zentek’s Albany graphite deposit in Ontario, Canada, as a promising source of high-purity graphite, Greg emphasized the need for government and industry investments in North American graphite projects.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets.

To learn more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

In this InvestorIntel interview, Tracy Weslosky talks with Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about an update on the commercialization of Zentek’s patented ZenGUARD™ antimicrobial technology.

With the ability to increase viral filtration efficiency of an HVAC (Heating, Ventilation, and Air Conditioning) filter by almost 5 times, Greg explains how a ZenGUARD™ coated HVAC filter is an incredibly safe way to improve indoor air quality and remove pathogens from the air without any additional energy requirements.

Although currently going through a regulatory approval process through Health Canada’s Pest Management Regulatory Agency (“PMRA”) in Canada, ZenGUARD™ has already received approval from another branch of Health Canada, indicating a high likelihood of approval from PMRA. Greg also discusses how ZenGUARD™ is seeing a growing demand from end users including filter manufacturers, provincial and municipal governments, and private sector customers.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is a graphene technology company focused on the research, development, and commercialization of graphene-based novel products to give its commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented ZenGUARD™ coating is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ont. Zentek’s second technology is the patent-pending ZenARMOR™ platform focused on corrosion protection applications.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview, Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about receiving the final report for Phase 2 testing of ZenGUARD™ for use in Heating, Ventilation and Air Conditioning (“HVAC”) filtration. Used as an antimicrobial coating, Greg discusses how ZenGUARD™ is a “best in class solution” to improve indoor air quality and remove pathogens from air, including SARS-CoV-2 (virus that causes COVID-19).

With ability to increase efficiency of a MERV 8 filter by almost 5 times, Greg discusses how ZenGUARD™ coating can be applied to existing HVAC filters without having to do any modification to the HVAC systems. Having shared the Phase 2 report with Federal and Provincial organizations, Greg goes on to provide an update on commercialization of ZenGUARD™ coated HVAC filters.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.

Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview, host Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about its new mask manufacturing and packaging agreement and interest generated from a successful promotional tour in the USA.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Greg discusses how Zentek has entered into an agreement with long-established Viva Healthcare Packaging (Canada) Ltd. to manufacture and sell surgical masks enhanced with Zentek’s proprietary ZenGUARD antimicrobial coating. At the height of the pandemic Viva was producing over 20 million masks per month. “They’re big and well established with an existing distribution network,” Greg tells Tracy, “so it was absolutely a perfect partnership for us.”

Greg also talks about his recent visit to Washington, D.C., that included 14 meetings with members of the U.S. Congress, to discuss indoor air quality and Zentek’s ZenGUARD-coated HVAC filters. “We developed a lot of momentum there,” he says. He also talks about ongoing testing of their HVAC filters in real world environments, like classrooms. “The simplicity and elegance of our solution is it’s a passive solution that can be added to any existing system.”

Finally, Greg also talks about Zentek’s finances. “We did a significant capital raise at the beginning of this year and our treasury’s in an excellent position,” he tells Tracy, “but we’re being very judicious in our spending.”

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

As the world becomes increasingly interconnected, we have seen how the risks of disease transmission have also increased. In response, companies like Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN) are leveraging cutting-edge nanotechnology to develop new ways of protecting people from harmful pathogens. It is dedicated to researching and developing new technologies, specifically around nanomaterials. Their graphene-based solutions have the potential to revolutionize many industries beyond healthcare, including electronics, energy storage, water treatment, and more. They have partnered with leading companies in each of these sectors to commercialize their technology.

This need is why Zentek created an antimicrobial coating known as ZenGUARD™, a proprietary graphene-oxide silver compound shown to be highly effective at filtering out bacteria and viruses. The product has been measured to filter 98.9% more bacteria and 97.8% more viruses than standard surgical masks.

Recently, Zentek’s team has been focused on commercializing the patent-pending ZenGUARD™ coating. InvestorIntel’s Tracy Weslosky recently spoke with Zentek CEO and Director Greg Fenton about their current efforts and their recently announced success of its commercialization efforts.

Zentek announced that it has entered into a Reciprocal Supply Agreement on March 31, 2022, with EkoMed Global Inc., an international manufacturer and distributor of personal protective equipment (PPE). In this agreement, Zentek will sell quantities of its coated material to be used initially for surgical masks made by EkoMed and eventually other PPE in the future. Zentek continues to work to expand its network of partnerships and is looking to get FDA approval for ZenGUARD-coated products.

In July Zentek filed a provisional patent on the use of ZenGUARD as an anti-inflammatory agent for dermatological conditions. Further expanding its potential as a dermatological product, it is currently being researched for treatment of various skin conditions, including both infectious and inflammatory conditions like acne, psoriasis, eczema, sunburn, poison ivy, warts, seborrheic dermatitis and toenail fungal infections.

Zentek is also positioned strategically from a supply chain perspective. The Albany Graphite project is located in Northern Ontario, Canada, and they own 100% of the project. The graphene from this source has a combination of graphite purity, particle size, and consistency which could make it ideal for certain solutions. This project could be a significant advantage as Zentek continues to develop graphene-based solutions for various industries.

As the ZenGUARD brand is based on graphene, controlling their own source of graphene can lead to cost and quality control advantages. Their team is also developing surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products that are all based on graphene-based compounds.

Zentek could have large potential upside if it can capitalize on its technology. They are well positioned to continue growing their business through a combination of strong IP protection, continued innovation, and strategic partnerships. The key will be whether Zentek can continue to expand the market for its ZenGUARD coated products and partner with enough manufacturers to win enough market share in Canada and abroad.

In this InvestorIntel interview with host Tracy Weslosky, Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton talks about new opportunities and commercial applications for their unique Zenguard antimicrobial coating.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Greg tells Tracy “we’re focused quite acutely on the HVAC sector right now. We’re testing our unique antimicrobial coating on HVAC filters. Our Zenguard coating has been demonstrated to be effective against most airborne pathogens.” The interest in applying Zenguard to HVAC filters came out of a Canadian government call for new technologies to fight Covid-19, and Zentek won phase one of the challenges and is now onto phase two testing in real-world environments.

“If we’re successful,” Greg tells Tracy, “then the Government of Canada becomes an immediate client of ours and they will procure from us for a period of three years minimum.” He continues that the person in charge of the government testing facility “has told us that he has not seen anything even close to what we’ve been able to achieve so far, so we’re very excited about this and think we could have this product in the market later this year.”

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have over 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview with host Tracy Weslosky, Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton talks about Zentek’s substantial recent newsflow, including listing on NASDAQ and announcing sales and distribution of ZenGUARD™ coated-masks through Mark’s in Canada.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Greg Fenton talks about other recent announcements including the start of Phase 2 testing of ZenGUARD™ antimicrobial coating on HVAC filters under a contract with Innovation Solutions Canada (ISC). He goes on to say that on the success of Phase 2, Zentek can add the Government of Canada as a client as well as opening up new opportunities for sales and distribution. Greg also provides an update on Zentek’s portfolio of patents including the filing of a provisional patent for their fire-retardant additive.

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

At the start of the year, I was asked to pick a name that I thought could be the “stock to watch in 2022”. Naturally the tendency is to step a little further out the risk curve because where’s the fun in picking something like Enbridge, Inc. (TSX: ENB | NYSE: ENB) and being up 15% year-to-date plus dividend when you could be up 130% over that same time period with a stock like Ensign Energy Services, Inc. (TSX: ESI). In reality, I would have been a hero if I had picked either of those in light of what the majority of the market has done since the start of 2022. However, I went down the technology route (or should I say rout) and the name I picked has been swept lower in a market beating up anything resembling tech. On top of that, the company I selected was also the focus of a short report, although that appears to have been addressed in March and seems to be a non-issue. But technology stocks are still seeing some pretty unpleasant days here and there, and the pain may not be over yet.

Nevertheless, until the year is over, I still have time to be vindicated with my 2022 pick – Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN), which is certainly doing better than Shopify, Inc. (TSX: SHOP | NYSE: SHOP) but sadly that’s not setting the bar too high. Reader’s will recall that Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases.

The focus on ZenGUARD™ is paying off with an announcement last week of the sales and distribution of ZenGUARD™ Masks through Mark’s, a member of the Canadian Tire Family of Companies. Mark’s, which operates over 380 stores across Canada, has placed an initial order for ZenGUARD™ coated masks to be sold at select stores and online. Mark’s VP Iain Summers is quoted as saying “We are relentlessly focused on innovative new technologies and products that help keep Canadians safe and comfortable. Zentek, and their ZenGUARD™ masks are a great made-in-Canada innovation using a technology that, when applied to essential masks, provides ultimate protection, while maintaining comfort and breathability. It’s the right fit for our customers.” This news helped Zentek stock rally 14% on the day.

It was the progress the Company was making with ZenGUARD™ and their other unique IP opportunities that led to Zentek being my stock to watch. Other technologies under development include an icephobic coating that can potentially be used to improve aircraft and drone safety and sustainability. The Company anticipates applications for aircraft, wind turbines, ocean vessels, and building structures to increase safety and efficiency outcomes in ice-forming weather conditions. The Company recently reported excellent results in three rounds of testing of its icephobic coating, including laboratory tests, real-world flights and applications related to drone operations in adverse weather. Next steps include testing its coating for sand and rain erosion, and other tests are being planned that will evaluate the coating as part of a hybrid ice protection system, where the icephobic properties are combined with a heated de-icing system with the aim to improve efficiency of current ice protection methods used in general and commercial aviation.

In April, Zentek provided an update on a previously awarded R&D test contract through the Innovation Solutions Canada (ISC) Testing Stream to test ZENGuard™ coated HVAC filters with interest from 3 different units within the National Research Council of Canada. After completion of Phase 1 testing where its ZenGUARD™ coating was successful in reducing airborne organisms from passing through coated filter material while not inhibiting air flow, it will now proceed to Phase 2 testing within its ISC Testing Stream contract. Phase 2 testing in a real-world classroom environment is aimed to generate additional safety and efficacy data. The importance of indoor air quality and improving health is a top priority for numerous organizations globally, including the Canadian and U.S. governments, and could be an important commercialization milestone for Zentek in this critical area.

Sure all these initiatives were already on the go at the start of the year, but in my opinion, the Company is making great strides in pushing these projects to the revenue generation stage. In fact, ZenGAURD™ actually started generating revenue in the final quarter of 2021. Additionally, Zentek raised C$33 million in January and have a quarterly cash burn rate of roughly C$2-C$2.5 million per quarter (and no debt), so they should be fine for available capital. With a market cap of roughly C$247 million there are plenty of creative and unique opportunities being developed to propel this Company into the future and vindicate my selection.

Welcome to 2022! I’m cautiously optimistic that this will be the year we get to put Covid in the rear-view mirror and get on with life without always waiting for the next shoe to drop (or a new variant to take hold). I’m happy to put 2021 in the history books and anticipate the bright future that could be. In that vein, I’d like to look ahead to what I think could be an exciting story for 2022. Now don’t get me wrong, I’m not saying this is my top pick or suggesting it will go up. This is simply my perspective on a company that has a lot going on that could be rewarded by the market this year.

The path of least resistance, after this week’s market action, would be to pick a uranium stock. Between how this group performed in 2021 and even more impressively, the first couple of trading days of 2022, it would certainly make for an easy article to write. I’m also a fan of junior base and precious metal mining companies, especially ones with plenty of results pending, but not today. The future is technology, so my exciting stock for 2022 is a technology company that posted a respectable 35% return in 2021 but is well positioned for 2022. It also happened to evolve out of a junior mining exploration company so it’s the best of both worlds.

If you haven’t figured out what company I’m talking about yet, it’s Zentek Ltd. (TSXV: ZEN), formerly known as ZEN Graphene Solutions Ltd. There is so much going on at Zentek it’s hard to know where to start. The Company currently describes itself as an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology. But that’s just the tip of the iceberg in my opinion.

The near-term catalyst is all about the antimicrobial coating ZENGuard^TM, which was developed as a virucidal graphene-oxide (“GO”) based compound to be applied as a coating onto fabrics, which included personal protective equipment such as face masks in an effort to increase protection afforded by such products. In September 2021 the Company received Health Canada approval for the sale of ZENGuard™ coated masks and entered into a binding definitive license and supply agreement with Trebor Rx Corp. for the supply of ZENGuard™ to coat face masks and potentially other health care products. To date, Trebor has purchased, and the Company has delivered, quantities of ZENGuard™ coating sufficient for the production of 10,000,000 masks currently done via third parties. However, development is underway of the Company’s industrial scale facility to produce ZENGuard™ and to coat materials. The Company anticipates assembly and installation of the industrial scale production equipment to be completed during Q1 2022, at which point production is expected to commence while commissioning, optimization and production ramp-up occurs over the following two to three months. Once this industrial process is in operation, the Company expects the production capacity of ZENGuard™ to increase significantly.

Zentek recently closed a bought deal public offering and a non-brokered private placement for aggregate proceeds of C$33 million to assist in the build out of their facility as well as research and development, acceleration of business growth opportunities and working capital. Other growth opportunities include the development of a new carbon-based nanotechnology-enhanced icephobic coating to reduce ice accretion. The Company anticipates applications for aircraft, wind turbines, ocean vessels, and building structures to increase safety and efficiency outcomes in ice-forming weather conditions. In late November Zentek announced it had been awarded an R&D test contract through the Innovation Solutions Canada Testing Stream to test ZENGuard™ coated HVAC filters with interest from 3 different units within the National Research Council of Canada. Other innovations include the development of a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing.

There is an awful lot going on at Zentek so I would encourage you to go check out their website to learn more because I’ve only scratched the surface of this stock to watch in 2022. Granted it’s not a small cap with a market cap of roughly $466 million after the closing of the latest capital raise earlier this week. Nevertheless, there are plenty of near-term catalysts with having their own production facility operational in the next few months and some pretty creative and unique opportunities being developed to propel this Company into the future.